Clinical Study With Axitinib In Advanced Kidney Cancer, Who Have Failed First Line Treatment
Status:
No longer available
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
This is a single arm study with axitinib in patients with advanced kidney cancer (clear cell
variant), who have failed first line therapy. The study will recruit a maximum of 30 patients
from 2 countries including Australia and Canada. Patients will be followed up for efficacy,
safety and health related outcomes.